Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 15.7 33.3 47.3% View Chart
P/BV x 2.2 3.4 63.5% View Chart
Dividend Yield % 0.5 0.5 98.5%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
CIPLA
Mar-19
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs712678 105.0%   
Low Rs484484 100.0%   
Sales per share (Unadj.) Rs349.6198.2 176.4%  
Earnings per share (Unadj.) Rs32.818.5 177.0%  
Cash flow per share (Unadj.) Rs44.335.0 126.7%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.30.5 64.8%  
Book value per share (Unadj.) Rs198.6186.3 106.6%  
Shares outstanding (eoy) m282.17805.70 35.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.9 58.3%   
Avg P/E ratio x18.231.4 58.1%  
P/CF ratio (eoy) x13.516.6 81.2%  
Price / Book Value ratio x3.03.1 96.5%  
Dividend payout %6.116.2 37.7%   
Avg Mkt Cap Rs m168,625468,031 36.0%   
No. of employees `00012.022.6 53.2%   
Total wages/salary Rs m20,56128,565 72.0%   
Avg. sales/employee Rs Th8,196.07,053.1 116.2%   
Avg. wages/employee Rs Th1,708.11,261.5 135.4%   
Avg. net profit/employee Rs Th768.5659.1 116.6%   
INCOME DATA
Net Sales Rs m98,655159,710 61.8%  
Other income Rs m2,0814,766 43.7%   
Total revenues Rs m100,736164,475 61.2%   
Gross profit Rs m15,85830,973 51.2%  
Depreciation Rs m3,25913,263 24.6%   
Interest Rs m3,3461,684 198.7%   
Profit before tax Rs m11,33520,791 54.5%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7565,695 66.0%   
Profit after tax Rs m9,25014,924 62.0%  
Gross profit margin %16.119.4 82.9%  
Effective tax rate %33.127.4 121.0%   
Net profit margin %9.49.3 100.3%  
BALANCE SHEET DATA
Current assets Rs m66,968124,266 53.9%   
Current liabilities Rs m40,21137,715 106.6%   
Net working cap to sales %27.154.2 50.0%  
Current ratio x1.73.3 50.5%  
Inventory Days Days8391 92.0%  
Debtors Days Days8195 85.6%  
Net fixed assets Rs m33,322105,190 31.7%   
Share capital Rs m2821,611 17.5%   
"Free" reserves Rs m55,770148,511 37.6%   
Net worth Rs m56,052150,123 37.3%   
Long term debt Rs m35,73838,301 93.3%   
Total assets Rs m132,888239,633 55.5%  
Interest coverage x4.413.3 32.9%   
Debt to equity ratio x0.60.3 249.9%  
Sales to assets ratio x0.70.7 111.4%   
Return on assets %9.56.9 136.8%  
Return on equity %16.59.9 166.0%  
Return on capital %17.811.8 150.5%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99857,410 109.7%   
Fx outflow Rs m22,85919,041 120.0%   
Net fx Rs m40,14038,368 104.6%   
CASH FLOW
From Operations Rs m13,24216,911 78.3%  
From Investments Rs m-6,990-16,687 41.9%  
From Financial Activity Rs m-7,387-3,487 211.8%  
Net Cashflow Rs m-2,971-3,451 86.1%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SUVEN LIFESCIENCES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS